Clinical trials: Alzheimer; Early Onset
Alzheimer Disease, Early Onset, Mild Cognitive Impairment
Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study
The objective of the study is to determine the safety, feasibility, and efficacy of senolytics in older adults with amnestic mild cognitive impairment (MCI) or early-stage AD (Clinical Dementia Rating (CDR)=0.5 or 1) who are tau…
- Trial name
- SToMP-AD (NCT04685590)
- Testing
- Dasatinib + Quercetin
- Where
- 5 sites in United States, Spain
- Volunteers
- 48 people
- Sponsor
- Washington University School of Medicine
Dementia of Alzheimer Type, Alzheimer Disease, Late Onset
Genetic Studies in Familial Dementia
The purpose of this study is to identify genetic factors that contribute to or cause dementia (loss of memory) and related disorders across all ages and ethnic groups.
- Conditions
- Dementia of Alzheimer Type, Alzheimer Disease, Late Onset, Alzheimer Disease, Early Onset, Mild Cognitive Impairment
- Trial name
- NCT04680013
- Where
- United States
- Volunteers
- 4,884 people, healthy volunteers welcome
- Sponsor
- University of Miami
Alzheimer Disease, Alzheimer Disease 1
A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study)
This is a randomized, double-blind, sham-controlled pivotal study of sensory stimulation in subjects with mild to moderate AD. Up to approximately 670 subjects will be treated with either Active or Sham investigational device…
- Conditions
- Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3
- Trial name
- HOPE (NCT05637801)
- Testing
- Spectris™ AD - Active
- Where
- 68 sites in United States
- Volunteers
- 673 people
- Sponsor
- Cognito Therapeutics, Inc.
Alzheimers Disease, Dementia
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
The purpose of this research study is to test the study drug, referred to as remternetug, to determine its effectiveness for the study treatment of asymptomatic (at risk) Alzheimer disease in individuals with AD-causing…
- Conditions
- Alzheimers Disease, Dementia, Alzheimers Disease, Familial
- Trial name
- DIAN-TU-002 (NCT06647498)
- Testing
- Remternetug
- Where
- 37 sites in United States, Argentina and 13 more
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Alzheimer Disease, Early Onset
A Study to Assess THN391 in Subjects With Alzheimer's Disease
This is a Phase 1b study to evaluate different doses of the drug and see whether a drug is safe and how it behaves in the body. THN391 has already been assessed in healthy people without Alzheimer's disease.
- Trial name
- NCT06814730
- Testing
- THN391
- Where
- 4 sites in Netherlands, United Kingdom
- Volunteers
- 19 people
- Sponsor
- Therini Bio, Inc.
Alzheimer Disease
Lecanemab for Early Onset Familial Alzheimer's Disease
The goal of this observational study is to learn about the efficacy of Lecanemab treatment for early-onset familial Alzheimer's disease (AD) in patients under 65 years of age with a family history of AD.
- Trial name
- NCT06883019
- Where
- 15 sites in China
- Volunteers
- 114 people
- Sponsor
- RenJi Hospital
Alzheimer Disease, Early Onset
The Ketogenic Diet for Alzheimer's Disease
The ketogenic diet (KD) is a metabolic shift, which stimulates the liver oxidation of fatty acids to produce ketone bodies. These ketone bodies represent an alternative fuel source for the brain.
- Trial name
- CETOMA (NCT04701957)
- Testing
- Ketogenic diet
- Where
- France
- Volunteers
- 17 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Alzheimer Disease, Early Onset, Atypical Alzheimer's Disease
Effects of Electrical Stimulation on Verbal Learning in Typical and Atypical Alzheimer's Disease
Alzheimer's disease (AD) is the leading neurodegenerative disease of aging characterized by multiple cognitive impairments. Given the recent failures of disease-modifying drugs, the current focus is on preventing or mitigating…
- Conditions
- Alzheimer Disease, Early Onset, Atypical Alzheimer's Disease, Logopenic Progressive Aphasia
- Trial name
- NCT04122001
- Testing
- Active, in-person HD-tDCS or active remote tDCS, Word List Learning Intervention (WordLLI)
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Early Onset Alzheimer Disease, Frontotemporal Dementia
RHAPSODY-plus: Online Counseling for Family Caregivers of Patients With Young Onset Dementia
The RHAPSODY-plus project consists of two parts. In a first step carers of people with young onset dementia (YOD; onset before the age of 65) have the opportunity to use the RHAPSODY online program (Kurz et al., 2016) to inform…
- Trial name
- RHAPSODY-plus (NCT03923517)
- Testing
- RHAPSODY online program and MEET online sessions
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Technical University of Munich
Cognitive Impairment, Alzheimer Disease, Early Onset
Juice Plus Supplement Clinical Trial
The study is designed to determine whether encapsulated fruit and vegetable juice concentrates can improve biological indicators of cognitive and multiple dimensions of memory and learning.
- Conditions
- Cognitive Impairment, Alzheimer Disease, Early Onset, Mild Cognitive Impairment
- Trial name
- NCT04656860
- Testing
- Juice Plus+
- Where
- 2 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Alabama, Tuscaloosa
Alzheimer Disease, Early Onset, Lewy Body Disease
Patients With Alzheimer's Disease or Related Youth Disease
This study aims to determine factors related to diagnosis delay for patients with young onset dementia (first symptoms before 60 years old) who live in North of France.
- Conditions
- Alzheimer Disease, Early Onset, Lewy Body Disease, Frontotemporal Lobar Degeneration
- Trial name
- PARMAAJJ (NCT03508024)
- Where
- France
- Volunteers
- 220 people
- Sponsor
- University Hospital, Lille
Mild Cognitive Impairment (MCI), Dementia
A Multifocal tDCS-EEG Protocol for Improving Symptoms of Mild Cognitive Impairment and Early Dementia
The goal of this clinical trial is to learn if an integrated protocol using multifocal non invasive brain stimulation and brain recording combined with cognitive training is effective in treating cognitive and affective…
- Conditions
- Mild Cognitive Impairment (MCI), Dementia, Alzheimer Disease, Early Onset, Alzheimer Disease
- Trial name
- MuSt-MID (NCT06668610)
- Testing
- StarStim 32, Neuroelectrics, Spain - Real multifocal tDCS, Cognitive treatment
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University of Campania Luigi Vanvitelli
Alzheimer Disease, Early Onset
PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)
This Phase 1b study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of multiple IV infusions of PMN310 in patients with early Alzheimer's disease.
- Trial name
- NCT06750432
- Testing
- PMN310
- Where
- 22 sites in United States
- Volunteers
- 144 people
- Sponsor
- ProMis Neurosciences, Inc
Alzheimer Disease, Early Onset
Novel Dementia Biomarkers
The study will investigate structural and functional characteristics of the brain of dementia patients compared to healthy controls in order to get a better insight into importance of early biomarkers for the diagnosis of…
- Trial name
- NCT04427436
- Testing
- No Intervention
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- German Center for Neurodegenerative Diseases (DZNE)
Down Syndrome (Trisomy 21), Neuropsychology
Neuropsychological Evaluation in Intellectual Disability (ENDI)
The goal of this observational study is to evaluate the acceptability ofpatients with trisomy 21 (T21) to perform the full battery of ENDI neurospychological tests and each of the subsets.
- Conditions
- Down Syndrome (Trisomy 21), Neuropsychology, Cognitive Aging, Alzheimer Disease
- Trial name
- ENDI (NCT07047963)
- Testing
- ENDI (Neuropsychological Evaluation in Intellectual Disability)
- Where
- France
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Central Hospital, Nancy, France
Alzheimer Disease, Early Onset, Posterior Cortical Atrophy
MECHANISMS OF NEURONAL RESILIENCE IN ALZHEIMER'S DISEASE AND ITS FOCAL VARIANTS: A PET/MR STUDY
Patients with Alzheimer's disease and with early onset of symptoms (<65 years) (AD-Y) have a multi-domain cognitive deficit, whereas memory disorders (typical of the elderly patient's AD) are less often in the foreground.
- Trial name
- PET-AL (NCT04150198)
- Testing
- TEP/IRM
- Where
- 2 sites in France
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Alzheimer Disease, Early Onset
Ryan Companion Robot for Assisting Elderly People With Alzheimer's Disease
The objective of this project is to conduct research and a pilot study to demonstrate the potential clinical impact and technical feasibility of a socially-assistive robot, called Ryan Companionbot (hereafter Ryan), for life…
- Trial name
- NCT05052866
- Testing
- Social Robot
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- DreamFace Technologies, LLC
Alzheimer Disease
A Lexico-semantic Program on Tactile Tablet for Patients With Alzheimer's Disease
Lexical semantic disorders are described in Alzheimer's disease, and their incidence in everyday life is important to the extent that these disorders affect expression and comprehension.
- Trial name
- SemantiMATT (NCT03047694)
- Testing
- tablet therapy, usual care
- Where
- 2 sites in France
- Volunteers
- 1 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Down Syndrome, Cognitive Decline
GnRH Therapy on Cognition in Down Syndrome
Down syndrome (DS) is the most common chromosomal disorder; with the increasing life expectancy, about 80% of DS adults reach age 65 years old.
- Conditions
- Down Syndrome, Cognitive Decline, Alzheimer Disease, Early Onset, Olfaction Disorders
- Trial name
- NCT04390646
- Testing
- GnRH, gonadorelin acetate, 0.9% NaCl
- Where
- Switzerland
- Volunteers
- 56 people
- Sponsor
- Nelly Pitteloud
Alzheimer Disease, Early Onset
Digital Evaluations and Technologies Enabling Clinical Translation for AD
The DETECT-AD study (stands for "Digital Evaluations and Technologies Enabling Clinical Translation for Alzheimer's Disease") is a new study designed to improve clinical trials for early Alzheimer's disease.
- Trial name
- DETECT-AD (NCT05385913)
- Testing
- Multivitamin-no intervention
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Oregon Health and Science University